GSK's Cervarix a future blockbuster of 2007

The number of blockbusters continues to increase. The number is set to increase to 112 in 2007. Of the products set to receive FDA approval this year and generate blockbuster status on an annual basis, GSK's Cervarix, intended for the prevention of infection and lesions from the two cancer-causing types of HPVs holds great potential.

GSK will earn royalties of up to 10% or $200 million each year from Merck due to sales of the Cervarix cervical cancer vaccine, according to the legal settlement reached last year. This is a new market battle and you need to be part of it.

A joint-venture between Sanofi-Aventis and Merck believe they have first-mover advantage. Do they? Will GSK be able to fight this advantage in a new generation of blockbuster vaccines with annual sales likely to exceed $2Bn each? The companies need to secure their share of this innovative and lucrative battle ground. Our new report highlights how they plan to do this, which products will be successful and how you can be part of it. You should order this report.

GSK believe that comparing Cervarix head-to-head with other vaccines, they can increase their market share. GSK are confident of this drug. We believe it will be a blockbuster - what do you think? What should you think? Read this report to find out.

2006 saw the launch of Gardasil the first vaccine against HPV (human papilloma virus) to protect against cervical cancer. Cervarix is due to be launched in 2007. Cervarix has, say GSK, the potential to reduce incidence of cervical cancer by 80%. With 500,000 new cases of cervical cancer reported each year, cervical cancer is the 3rd-leading cause of cancer death of woman worldwide. Governments will fund this drug if priced correctly. If this happens then Blockbuster satus is guaranteed.

The report gives an overview of the potential blockbusters set to hit the cancer vaccine market. Tn particular concentrating on the following aspects of cancer vaccines:

Key players in blockbuster cancer vaccines

What technologies can be utilised by cancer vaccines

Revenue forecasts for potential blockbuster cancer vaccines

Therapeutic cancer vaccines likely to achieve commercial success

A clear SWOT analysis of cancer drugs

Competitor analysis of likely blockbuster launches in cancer vaccines through to 2012

Why you must by this report:

The pharmaceutical industry has been seeking the next blockbuster drug, yet it appears as though these might not be as profligate as they have been in the past. However, the cancer vaccine markets hold promise. This report analyses the current situation in the market and assesses the potential of the products that are currently in the development pipeline. A comprehensive analysis of the cancer vaccine market from 2007-2012 outlines the potential of the market. Visiongain expects to see the development of at least two multi-billion dollar drugs. You and your company should be part of this market, and you could be by placing your order immediately.

Unique benefits to you when you order this report:

- Full searchable report when you buy the company or corporate editions

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Publication Date: 22/03/07

Pages: 86

PDF Format
Table of Contents

Price
Single User Licence $3998.00
Department Licence 5 Users $7998.00
Company-wide Intranet Licence $13,998.00